[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0312030A - Combination of pde5 inhibitors with angiotensin ii receptor antagonists - Google Patents

Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Info

Publication number
BR0312030A
BR0312030A BR0312030-9A BR0312030A BR0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A
Authority
BR
Brazil
Prior art keywords
angiotensin
combination
receptor antagonists
pde5 inhibitors
pde5
Prior art date
Application number
BR0312030-9A
Other languages
Portuguese (pt)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0312030A publication Critical patent/BR0312030A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO DE INIBIDORES DE PDE5 COM ANTAGONISTAS DE RECEPTOR DE ANGIOTENSINA II". A presente invenção refere-se a combinações que compreendem (a) um inibidor de monofosfato de guanosina cíclico (cGMP) específico para fosfodiesterase do tipo 5 (PDE5) e b) um antagonista do receptor de angiotensina II que são úteis para o tratamento de hipertensão."COMBINATION OF PDE5 INHIBITORS WITH ANGIOTENSIN II RECEPTOR ANTAGONISTS". The present invention relates to combinations comprising (a) a phosphodiesterase type 5 cyclic guanosine monophosphate (cGMP) inhibitor (PDE5) and b) an angiotensin II receptor antagonist which are useful for the treatment of hypertension.

BR0312030-9A 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists BR0312030A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Publications (1)

Publication Number Publication Date
BR0312030A true BR0312030A (en) 2005-03-22

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312030-9A BR0312030A (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Country Status (20)

Country Link
EP (1) EP1524996A2 (en)
JP (1) JP2005531627A (en)
KR (1) KR20050013156A (en)
CN (1) CN1662257A (en)
AR (1) AR040337A1 (en)
AU (1) AU2003242895A1 (en)
BR (1) BR0312030A (en)
CA (1) CA2491002A1 (en)
GB (1) GB0214784D0 (en)
GT (1) GT200300124A (en)
MX (1) MXPA04012569A (en)
NO (1) NO20050400L (en)
PA (1) PA8575501A1 (en)
PE (1) PE20040868A1 (en)
PL (1) PL375079A1 (en)
RU (1) RU2004136276A (en)
TW (1) TW200404546A (en)
UY (1) UY27863A1 (en)
WO (1) WO2004002461A2 (en)
ZA (1) ZA200409532B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US7756327B2 (en) * 2002-07-26 2010-07-13 Olympus Corporation Image processing system having multiple imaging modes
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (en) * 2005-03-31 2006-11-28 Univ Minas Gerais process of developing substances as potent and selective inhibitors of phosphodiesterase isoforms of types 1 to 5 (pde1, pde2, pde3, pde4, pde5) based on diocleine, fluranol or analogs and their pharmaceutical compositions for the study and treatment of cardiovascular disease and associated products
JP4879977B2 (en) * 2005-06-10 2012-02-22 ドン・ア・ファーム・カンパニー・リミテッド Preventive and therapeutic agents for liver diseases containing pyrazolopyrimidinone derivatives
EP1909793A2 (en) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
AU2006304787A1 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
PL194801B1 (en) * 1997-11-12 2007-07-31 Bayer Healthcare Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
SK4562002A3 (en) * 1999-10-11 2003-04-01 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20030023747A (en) * 2000-08-11 2003-03-19 화이자 인코포레이티드 Treatment of the insulin resistance syndrome

Also Published As

Publication number Publication date
TW200404546A (en) 2004-04-01
AU2003242895A1 (en) 2004-01-19
GT200300124A (en) 2004-03-17
MXPA04012569A (en) 2005-04-19
CN1662257A (en) 2005-08-31
EP1524996A2 (en) 2005-04-27
WO2004002461A3 (en) 2004-05-13
PE20040868A1 (en) 2004-11-25
JP2005531627A (en) 2005-10-20
PL375079A1 (en) 2005-11-14
RU2004136276A (en) 2005-09-10
CA2491002A1 (en) 2004-01-08
KR20050013156A (en) 2005-02-02
WO2004002461A2 (en) 2004-01-08
PA8575501A1 (en) 2003-12-30
NO20050400L (en) 2005-03-29
GB0214784D0 (en) 2002-08-07
UY27863A1 (en) 2003-12-31
AR040337A1 (en) 2005-03-30
ZA200409532B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
ATE346070T1 (en) PURINE DERIVATIVES AS KINASE INHIBITORS
CY1105390T1 (en) THERAPEUTIC MANAGEMENT OF PULMONARY HYPERTENSION
ECSP066580A (en) 5,7-DIAMINOPIRAZOLO [4,3-d] PYRIMIDINS WITH INHIBITING ACTIVITY OF THE PDE-5
CY1117108T1 (en) Imidazotriazines and imidazopyrimidines as an inhibitor of kinase
MX2007002311A (en) Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof.
DE60332433D1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
BRPI0413922A (en) substituted 8-heteroaryl xanthines
ATE430747T1 (en) 2-PYRIMIDINYL-PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS
SV2002000287A (en) USE OF THE CYCLINE DEPENDENT KINASE INHIBITOR TO PREPARE A USEFUL PHARMACEUTICAL COMPOSITION TO TREAT NEURODEGENERATIVE DISEASES
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
NO20076554L (en) Pyrimidine or triazine condensed bicyclic metalloprotease inhibitors
NI201000059A (en) C-FMS KINASE INHIBITORS.
UY30297A1 (en) C-FMS-I QUINASE INHIBITORS
BRPI0412894A (en) thienopyridine and furopyridine kinase inhibitors
DK1761520T3 (en) kinase inhibitors
IL163777A0 (en) Kinase inhibitors
BR0312030A (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists
ECSP056173A (en) COMPOSITION THAT INCLUDES A PDE4 INHIBITOR AND A PDE5 INHIBITOR
BR0314196A (en) Tgf-beta inhibitors
BR0317284A (en) Mitogen-Activated Protein Kinase-2 Aminocyanopyridine Inhibitors
BR0311191A (en) Combination
GT200300231A (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
BR0307595A (en) Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovarian syndrome
NO20065850L (en) Procedure for Identifying PDE5 Modulators
UY29581A1 (en) (5Z) -5- (6-QUINOXALINYLMETILIDENE) -2 - ((2,6-DICLOROPHENYL) AMINO) -1,3-TIAZOL-4 (5H) -ONA

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.